Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy INO?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, urging investors who purchased shares between October 10, 2023, and December 26, 2025, to contact them before the April 7, 2026, deadline to seek lead plaintiff status.
- Regulatory Compliance Issues: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in the CELLECTRA device, which diminished the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024.
- Significant Stock Price Drop: Following the FDA's acceptance of Inovio's INO-3107 BLA, the company's stock price plummeted by 24.45% to close at $1.73 per share on December 29, 2025, indicating market concerns regarding its regulatory and commercial prospects.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information about Inovio's conduct, including whistleblowers and former employees, to come forward to support the ongoing class action lawsuit, ensuring that investors' rights are safeguarded.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.680
Low
3.00
Averages
7.33
High
13.00
Current: 1.680
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future regulatory and commercial prospects.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in Inovio's stock price, reflecting market concerns about its future prospects.
- Investor Rights Reminder: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investors actively protecting their rights in light of potential financial losses.
See More
Faruqi & Faruqi Encourages Inovio Investors to Discuss Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, urging them to seek lead plaintiff status by the April 7, 2026 deadline, which could significantly impact their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to protecting investor interests.
- Class Action Context: The class action lawsuit is filed against Inovio in federal court, and investors must act before the deadline to secure their claims, highlighting the potential implications of legal proceedings on investor rights.
- Company Disclosure Issues: Faruq & Faruqi reminds investors to pay attention to Inovio's disclosure practices, which may affect stock prices and investor confidence, emphasizing the importance of legal compliance in corporate governance.
See More
Investors Alert: Class Action Lawsuits Against Inovio and Paysafe
- Inovio Lawsuit Overview: A class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) alleges that the company made materially false or misleading statements between October 10, 2023, and December 26, 2025, resulting in significant investor losses, with a deadline of April 7, 2026, to apply for lead plaintiff status.
- Paysafe Legal Issues: Paysafe Limited (NYSE: PSFE) is facing a class action lawsuit for failing to disclose important facts regarding its e-commerce business and significant exposure to a single high-risk client, with affected investors needing to apply for lead plaintiff status by April 7, 2026, if they purchased shares between March 4, 2025, and November 12, 2025.
- Law Firm Background: Holzer & Holzer, LLC is an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicated to vigorously representing shareholders and investors in litigation since its founding in 2000, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct.
- Investor Rights Protection: The firm encourages affected investors to contact them via their website or phone to discuss their legal rights and participate in the lawsuits to protect their investment interests.
See More
Multiple Companies Face Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation faces a class action lawsuit for the period from June 12 to December 16, 2025, with allegations of misleading statements leading to investor losses exceeding $50,000, as its AI infrastructure strategy is expected to significantly increase capital expenditures without corresponding revenue growth, potentially jeopardizing its debt and credit rating.
- Paysafe Risks: Paysafe Limited is under scrutiny in a class action lawsuit covering March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client, which has led to understated credit loss reserves and could negatively impact revenue growth, making it unlikely to meet its 2025 financial guidance.
- Inovio Manufacturing Deficiencies: Inovio Pharmaceuticals is involved in a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which may hinder its ability to submit a BLA to the FDA on time, overstating its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings faces a class action lawsuit for the period from August 7, 2024, to February 9, 2026, alleging material misstatements in financial reports and inadequate internal controls, which could prevent timely filing of its quarterly report, further damaging investor confidence.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that BlackRock failed to timely and appropriately value investments from November 2024 to January 2026, resulting in understated unrealized losses and inflated net asset value (NAV), which adversely affected investors' financial positions.
- Oracle Lawsuit Impact: In the lawsuit concerning Oracle from June to December 2025, investors were informed that the company's AI infrastructure strategy would lead to significant capital expenditure increases without corresponding near-term revenue growth, raising concerns about debt and credit rating risks, thereby undermining investor confidence.
- Paysafe and Inovio Lawsuit Situations: Paysafe's lawsuit highlights significant exposure to high-risk clients in its e-commerce business, potentially hindering revenue growth, while Inovio faces challenges due to manufacturing deficiencies that may prevent timely FDA submissions, posing risks to investor interests.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased Inovio Pharmaceuticals (NASDAQ: INO) shares between October 10, 2023, and December 26, 2025, to contact them regarding potential lead plaintiff appointment for recovery participation.
- Allegation Details: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which overstated the regulatory prospects of its lead product candidate, INO-3107.
- FDA Submission Challenges: Due to manufacturing deficiencies, Inovio is unlikely to submit its Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024, which could significantly impact its commercial viability and investor confidence.
- Shareholder Registration Deadline: Shareholders must register for the class action by April 7, 2026, to avoid losing their right to claim, and those who register will receive updates on the case's progress throughout its lifecycle.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, involving investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- False Statement Allegations: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future regulatory and commercial prospects.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in Inovio's stock price, reflecting market concerns about its future prospects.
- Investor Rights Reminder: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investors actively protecting their rights in light of potential financial losses.
See More
Faruqi & Faruqi Encourages Inovio Investors to Discuss Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, urging them to seek lead plaintiff status by the April 7, 2026 deadline, which could significantly impact their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to protecting investor interests.
- Class Action Context: The class action lawsuit is filed against Inovio in federal court, and investors must act before the deadline to secure their claims, highlighting the potential implications of legal proceedings on investor rights.
- Company Disclosure Issues: Faruq & Faruqi reminds investors to pay attention to Inovio's disclosure practices, which may affect stock prices and investor confidence, emphasizing the importance of legal compliance in corporate governance.
See More
Investors Alert: Class Action Lawsuits Against Inovio and Paysafe
- Inovio Lawsuit Overview: A class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) alleges that the company made materially false or misleading statements between October 10, 2023, and December 26, 2025, resulting in significant investor losses, with a deadline of April 7, 2026, to apply for lead plaintiff status.
- Paysafe Legal Issues: Paysafe Limited (NYSE: PSFE) is facing a class action lawsuit for failing to disclose important facts regarding its e-commerce business and significant exposure to a single high-risk client, with affected investors needing to apply for lead plaintiff status by April 7, 2026, if they purchased shares between March 4, 2025, and November 12, 2025.
- Law Firm Background: Holzer & Holzer, LLC is an ISS top-rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicated to vigorously representing shareholders and investors in litigation since its founding in 2000, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct.
- Investor Rights Protection: The firm encourages affected investors to contact them via their website or phone to discuss their legal rights and participate in the lawsuits to protect their investment interests.
See More
Multiple Companies Face Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation faces a class action lawsuit for the period from June 12 to December 16, 2025, with allegations of misleading statements leading to investor losses exceeding $50,000, as its AI infrastructure strategy is expected to significantly increase capital expenditures without corresponding revenue growth, potentially jeopardizing its debt and credit rating.
- Paysafe Risks: Paysafe Limited is under scrutiny in a class action lawsuit covering March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client, which has led to understated credit loss reserves and could negatively impact revenue growth, making it unlikely to meet its 2025 financial guidance.
- Inovio Manufacturing Deficiencies: Inovio Pharmaceuticals is involved in a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which may hinder its ability to submit a BLA to the FDA on time, overstating its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings faces a class action lawsuit for the period from August 7, 2024, to February 9, 2026, alleging material misstatements in financial reports and inadequate internal controls, which could prevent timely filing of its quarterly report, further damaging investor confidence.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that BlackRock failed to timely and appropriately value investments from November 2024 to January 2026, resulting in understated unrealized losses and inflated net asset value (NAV), which adversely affected investors' financial positions.
- Oracle Lawsuit Impact: In the lawsuit concerning Oracle from June to December 2025, investors were informed that the company's AI infrastructure strategy would lead to significant capital expenditure increases without corresponding near-term revenue growth, raising concerns about debt and credit rating risks, thereby undermining investor confidence.
- Paysafe and Inovio Lawsuit Situations: Paysafe's lawsuit highlights significant exposure to high-risk clients in its e-commerce business, potentially hindering revenue growth, while Inovio faces challenges due to manufacturing deficiencies that may prevent timely FDA submissions, posing risks to investor interests.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased Inovio Pharmaceuticals (NASDAQ: INO) shares between October 10, 2023, and December 26, 2025, to contact them regarding potential lead plaintiff appointment for recovery participation.
- Allegation Details: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which overstated the regulatory prospects of its lead product candidate, INO-3107.
- FDA Submission Challenges: Due to manufacturing deficiencies, Inovio is unlikely to submit its Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024, which could significantly impact its commercial viability and investor confidence.
- Shareholder Registration Deadline: Shareholders must register for the class action by April 7, 2026, to avoid losing their right to claim, and those who register will receive updates on the case's progress throughout its lifecycle.
See More
